Massive Bio

🎉 We are pleased to welcome three new talented professionals to our Massive Bio family! 🎉 Welcome aboard, Will Franco, Seren Bingül, Caner Can! Your journey with us is about to begin, and together, we will make a significant impact on the world of cancer care. We look forward to achieving great milestones together. #WelcomeToTheTeam #MassiveBio #CancerCare #NewBeginnings #TeamGrowth #HealthcareInnovation #CancerResearch #Oncology #HealthcareProfessionals #TogetherWeCan #ClinicalTrials #HealthcareExcellence Selin Kurnaz, PhD, Arturo LoAIza-Bonilla MD, Çağatay M. Çulcuoğlu

We are thrilled to share that on June 13th, our Account Manager in Spain, Gisela Saladino, and our Sr. Regional Manager, Mert Sarı, attended the European Hematology Association (EHA) Association Congress in Madrid. This event provided an excellent opportunity to connect with various European hematologists. Through this congress, we established numerous valuable connections and look forward to the collaborations and advancements that will arise from these new relationships. Selin Kurnaz, PhD, Arturo LoAIza-Bonilla MD, Çağatay M. Çulcuoğlu #MassiveBio #EHA #Hematology #ClinicalTrials #Madrid

🎉As #MassiveBio, we achieved significant success at #ASCO24! Recognizing the challenges in #cancerclinicalresearch, we presented our innovative solutions at this year's conference. Our contributions, including the demonstration of our artificial intelligence platform, Clinical Network, and the introduction of Drug Utilization Optimizer (DUO), garnered significant attention. Our presence at the event was not just marked by the interest we attracted, but also by the valuable collaborations we initiated. These partnerships, we believe, are not just potential, but the beginning of a transformative journey together. We extend our heartfelt gratitude to all our supporters. 🚀See you at ASCO 2025! Selin Kurnaz, PhD, Arturo LoAIza-Bonilla MD, Çağatay M. Çulcuoğlu, Toygun Onaran, Oz Huner, Aslan Aslanağı, Eren Caskurlu, Hakki Isik, PMP, Mert Sarı, Ertuğrul T., Toykan Dogan, MCogSc, Fiona Evans, Brian O'Sullivan   #MassiveBio #ASCO24 #PCC #MikaHealth #UEPM #Inocras #CancerClinicalTrials #CancerResearch #AIinHealthcare 

Over the past weeks, Aslan Aslanağı and Marta Halke-Markiewicz from our team had a fruitful visit to #Poland, an increasingly important market for clinical research. During this visit, we met with our business partners, CliniNote, and explored new opportunities by strengthening our collaborations. 🔎 We also visited our business partners at MEDI CLINICAL to discuss how we can contribute more in line with the principles of providing high-quality care and continuous improvement. 🩺 Together with Paula Dobosz, we initiated collaborations with local physicians. These collaborations will further advance our clinical research work. We were also honored to participate in the Sound of Hope benefit concert organized by the patient support group Drużyna Szpiku. The event allowed us to share valuable insights and inspiring moments with patients. We thank Dorota Raczkiewicz for allowing us to participate in this event. 🎯 We believe that these activities in Poland will reinforce Massive Bio's role as a pioneer in clinical research, in line with its global vision, and contribute to providing better treatment options for patients. Selin Kurnaz, PhD, Arturo LoAIza-Bonilla MD, Çağatay M. Çulcuoğlu #MassiveBio #CliniNote #MediClinical #SoundofHope #Polonya #ClinicalTrials 

🌟 We are excited to welcome our new interns to #MassiveBio, where their expertise and passion will drive us forward in our mission to revolutionize cancer care.   🎉 We are pleased to introduce our new team members joining through our Global Internship Program and their respective roles at Massive Bio:   Defne Ungun – CRM Intern Erdem Büke – QA Intern Esra Celebi – Software Intern Eran Levi – Business Development Intern Selin Kurnaz, PhD, Arturo LoAIza-Bonilla MD, Çağatay M. Çulcuoğlu, Aycan Emre #MassiveBio #NewHirings

In a conversation with Cancer Network®️ during the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting, our Co-Founder and Chief Medical Officer, Arturo LoAIza-Bonilla MD, spoke about his research in developing an AI-enabled system intended to reduce the time and resources needed to match patients to trials. He stated that it may be possible to more than double the number of patients matched to trials when integrating next-generation sequencing (#NGS) testing results into the matching process compared with manual processes. For more information, please click on the link below. 👉🏻 https://bit.ly/4co1U6n Selin Kurnaz, PhD, Arturo LoAIza-Bonilla MD, Çağatay M. Çulcuoğlu #MassiveBio #AIinHealthCare #ClinicalOncology #CancerResearch

🎉 Today at the 2024 ASCO Annual Meeting in Chicago, we announced our partnership with Inocras Inc., the leading AI-driven whole genome testing company. This partnership aims to set a new standard for cancer patients. The partnership aims to offer the most comprehensive genetic testing using whole genome sequencing while providing strong support for clinical trial matching for patients and healthcare providers. Inocras' robust biomarker data, combined with our capabilities, will provide an even richer analysis in the early stages of whole genome testing, facilitating matching patients to effective clinical trials. Massive Bio's partnership with Inocras is a ground-breaking alliance that will #revolutionizecancertreatment. With whole genome insights and #clinicaltrialmatching, we aim to avoid the challenge of finding the right clinic for each patient. For more information about this partnership, please click on the link below. 👉🏻 https://bit.ly/45cU2SQ Selin Kurnaz, PhD, Arturo LoAIza-Bonilla MD, Çağatay M. Çulcuoğlu, Toygun Onaran, Aslan Aslanağı, Eren Caskurlu #MassiveBio #Inocras #ASCO24 #CancerPatients #ClinicalTrials #GenomeSequencing #AIinHealthcare #HealthTechnology

🎉 At the 2024 ASCO Annual Meeting in Chicago, as a recognized leader in AI-driven oncology solutions, we are pleased to announce an expanded partnership with Un Ensayo para Mí (UEPM), Latin America's leading #clinicaltrialsearch platform. Massive Bio's advanced #artificialintelligencetechnology streamlines the clinical trial registration process, reducing the time and effort required for patient matching. Through this partnership, cancer patients in #LATAM will have better access to clinical trials, closing the gap between innovative treatments and the patients who need them most. Arturo LoAIza-Bonilla MD, our Co-Founder and Chief Medical Officer, said: 'As someone with strong ties to LATAM, this partnership has a personal significance for me. We are bringing our AI solutions at scale to advance our shared missions of helping cancer patients, supporting doctors, advancing research and development, and transforming LATAM into an innovation center for clinical trials.' By integrating our AI-driven solutions into the Un Ensayo Para Mi platform, we can deliver more accurate and timely #clinicaltrialmatches, increasing participation rates and advancing cancer research. For more information about this partnership, please click on the link below. 👉🏻 https://bit.ly/4c1y9b6 Selin Kurnaz, PhD, Arturo LoAIza-Bonilla MD, Çağatay M. Çulcuoğlu, Toygun Onaran, Aslan Aslanağı, Eren Caskurlu #MassiveBio #UEPM #ClinicalTrials #CancerTreatments #ClinicalTrialMatches #LATAM

At the 2024 ASCO Annual Meeting in Chicago, #MassiveBio is proud to announce a partnership with Mika Health, a leading oncology digital therapeutics platform. This collaboration aims to expand patient access to psycho-oncology services, next-generation sequencing (NGS) biomarker testing, and clinical research.   With this partnership, we offer the following: 🔹 Artificial Intelligence Driven Clinical Trial Matching 🔹 Advanced Genetic Tests 🔹 Symptom Management 🔹 Psychosocial and Lifestyle Support   In addition, we bridge the health gaps patients experience in seeking and accessing treatment, enabling them to access these critical resources faster and more effectively.   This partnership is an essential step towards personalized cancer treatment globally. It aims to empower cancer patients receiving treatment in the United States and Europe to participate in #clinicaltrials.   Click here for more information. 👉🏻  https://bit.ly/4e48mkt Selin Kurnaz, PhD, Arturo LoAIza-Bonilla MD, Çağatay M. Çulcuoğlu, Toygun Onaran, Oz Huner, Aslan Aslanağı, Eren Caskurlu, Hakki Isik, PMP, Mert Sarı, Ertuğrul T., Toykan Dogan, MCogSc, #MassiveBio #MikaHealth #ASCO2024 #Oncology #CancerTreatment #NGS #PsychoOncology #AIinHealthcare

Massive Bio is introducing our latest innovation, the Drug Utilization Optimizer (#DUO), at the ASCO Annual Meeting 2024 in Chicago! Building on the success of our SYNERGY-AI platform, DUO is set to transform how pharmaceutical commercial teams target and engage physicians. This innovative analytics and real-time notification platform provides unparalleled insights and efficiencies, allowing commercial teams to analyze the competitive landscape with up-to-date and accurate data. DUO connects with the right physicians, identifies relevant patients quickly and efficiently, increases brand revenues, and reduces the cost of sales. Unlike traditional real-world data companies, we improve operational efficiency and facilitate patient access to medicines by providing real-time and detailed insights. We recognize the challenges in cancer clinical trials and continue to work rapidly to bring more hope. Visit our booth at #ASCO24 to learn more about DUO and see a demo and click on the link below. 👉🏻 https://bit.ly/3yL8eGo Booth: #29137 Selin Kurnaz, PhD, Arturo LoAIza-Bonilla MD, Çağatay M. Çulcuoğlu, Toygun Onaran, Oz Huner, Aslan Aslanağı, Eren Caskurlu, Hakki Isik, PMP, Mert Sarı, Ertuğrul T., Toykan Dogan, MCogSc, #MassiveBio #ClinicalTrials #Innovation #Oncology #AIinHealthcare